Testing a new radioactive treatment for neuroendocrine lung cancer

Plain-English translation of NCT07278479 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

[212Pb]Pb-DOTAM-MAM279 is an experimental radioactive treatment that attaches to cancer cells with a specific protein marker and delivers radiation directly to them. This trial is testing whether the medication is safe and effective for patients with advanced small cell lung cancer and other related cancers. Researchers will gradually increase doses to find the safest and most effective level, then enroll more patients to confirm results.

Small cell lung cancer and related neuroendocrine cancers are aggressive and often return after standard treatments. This medication targets a specific protein found on these cancer cells, offering a potentially new option for patients whose cancers have progressed despite chemotherapy and other standard treatments.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced small cell lung cancer, large cell neuroendocrine lung cancer, or other neuroendocrine cancers (such as those in the stomach, pancreas, bladder, or cervix) that have come back or gotten worse
your cancer has progressed despite at least one to two prior lines of standard chemotherapy and immunotherapy, or you cannot tolerate standard treatments
your cancer cells have the specific protein marker (DLL3) that this treatment targets
you have adequate organ and bone marrow function based on blood tests and kidney function
you have at least one measurable tumor on imaging scans

You likely don't qualify if…

you have not recovered from serious side effects of prior cancer treatments
you have active, uncontrolled heart disease or serious lung inflammation
you have an active infection or other uncontrolled serious illness
you have had another type of cancer within the past 2 years (with some exceptions)
your kidney function is significantly impaired (glomerular filtration rate less than 60 mL/min)

What participation looks like

You will first receive an imaging scan using a non-radioactive version of the medication to confirm your cancer expresses the target protein and to plan your treatment dose. Then you will receive the radioactive treatment medication as an infusion. The trial has two parts: a dose-finding phase where doses are gradually increased, followed by a confirmation phase with more patients at the safest dose. You will have regular visits for blood tests, imaging scans, and monitoring of side effects to assess how well the treatment is working.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(5 sites)

United States

Emory University Hospital, Atlanta, Georgia

United Theranostics, Glen Burnie, Maryland

Nebraska Cancer Specialists, Omaha, Nebraska

United Theranostics, Princeton, New Jersey

University Hospitals Cleveland Medical Center, Cleveland, Ohio